How Tirzepatide Works (GLP-1 + GIP Explained)

Tirzepatide is the first dual incretin agonist to reach market. It activates two gut-hormone receptors at once — GLP-1 and GIP — where every other approved drug in this class hits only GLP-1. That mechanism difference is the entire reason tirzepatide produces more weight loss than semaglutide in head-to-head data.

The physiology is interesting partly because the GIP arm of the story is counterintuitive: for decades, drug developers thought GIP activation would make obesity worse, not better.

The two receptors, briefly

Both GLP-1 and GIP are incretins — gut hormones released after a meal that tell the pancreas to secrete insulin. They're closely related but do different downstream things.

Native GLP-1 and GIP last only minutes in the bloodstream. Tirzepatide is an engineered peptide that resists rapid breakdown — its half-life is about 5 days, so a single weekly injection keeps both receptors activated continuously.

What GLP-1 activation does

This is the better-understood half of the mechanism. Same as semaglutide, liraglutide, and exenatide before them:

1. Reduced appetite. GLP-1 receptors in the hypothalamus dampen hunger signaling. Most patients describe eating less without trying.
2. Slowed gastric emptying. Food sits longer in the stomach, prolonging fullness. This is also the source of most GI side effects — nausea, reflux, early satiety.
3. Glucose-dependent insulin secretion. The pancreas releases insulin in response to a meal, but only when blood glucose is elevated — which is why GLP-1 drugs rarely cause hypoglycemia on their own.
4. Glucagon suppression. Less glucagon means less hepatic glucose output, helping A1c.
5. Reward-pathway modulation. Subtler — but GLP-1 receptors in reward centers may explain reductions in cravings and "food noise."

For the deeper appetite story, the side effects pillar covers individual symptoms; for cravings specifically, see our mood and anxiety cluster on the broader brain-pathway story.

What GIP activation adds

Here's where it gets interesting. GIP was historically considered the "less useful" incretin. People with type 2 diabetes have a blunted insulin response to GIP — the receptor is there, but it doesn't fire as well. So GIP-targeting drugs for T2D were a disappointment for years.

Then preclinical work showed something surprising: chronic GIP receptor activation appears to amplify the weight-loss effect of GLP-1 activation, even though acute GIP secretion (the kind your body does after a meal) is associated with insulin resistance and weight gain.

The leading hypotheses for why dual activation works:

• Receptor desensitization. Chronic exposure may downregulate the same GIP signaling that, in the short term, promotes fat storage. The drug effectively quiets a pathway that's overactive in obesity.
• Direct fat-tissue effects. GIP receptors on adipocytes seem to improve insulin sensitivity and lipid handling when chronically activated.
• CNS appetite effects. GIP receptors in the brain may complement GLP-1 in suppressing appetite — possibly through different neural circuits than GLP-1, so the two effects add rather than overlap.
• Reduced GI side effects. GIP activation may blunt some of the nausea-inducing effects of GLP-1, which would help explain the slightly lower nausea rate observed with tirzepatide.

The honest truth: we don't fully understand why dual agonism works as well as it does. What we know is that the SURMOUNT and SURPASS trials show it does. See our SURMOUNT trial results breakdown for the data.

Why this matters for weight loss

Stack the two pathways and you get effects that don't appear in GLP-1 monotherapy:

The 7-percentage-point weight-loss gap between tirzepatide and semaglutide in head-to-head data is not subtle. See tirzepatide vs semaglutide for the full comparison.

Why dosing climbs gradually

Both receptors take time to acclimate. Starting at full dose causes severe nausea, vomiting, and gastric stasis. The standard six-step ladder (2.5 → 15 mg over 20 weeks) lets the gut, brain, and pancreas adjust. See tirzepatide dosing schedule for the full table.

The "GIP paradox" in one sentence

The same receptor activity that, fired briefly after a meal, contributes to insulin resistance and fat storage seems to do the opposite when activated continuously over weeks — quieting itself through receptor desensitization while complementing GLP-1's appetite and glucose effects. That paradox is the conceptual heart of tirzepatide.

What the mechanism doesn't do

A few things people sometimes assume tirzepatide does that it doesn't:

• It doesn't burn calories or "boost metabolism" directly. Weight loss is driven by reduced caloric intake from appetite suppression, not increased expenditure.
• It doesn't melt fat regionally. No spot reduction. You lose weight from wherever your body normally loses it.
• It doesn't fix insulin resistance permanently. The improvements in insulin sensitivity persist while you're on the drug. Stopping reverses most of the metabolic changes — see tirzepatide vs semaglutide and the SURMOUNT-4 data on weight regain.
• It doesn't cause hypoglycemia in non-diabetic users. The insulin release is glucose-dependent, so blood sugar normally stays in range. People with T2D on insulin or sulfonylureas need careful coordination — that's a different story.

Related questions

• Tirzepatide vs semaglutide head-to-head
• SURMOUNT trial results explained
• Tirzepatide side effects vs semaglutide